These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy. Luan Q; Jin L; Jiang CC; Tay KH; Lai F; Liu XY; Liu YL; Guo ST; Li CY; Yan XG; Tseng HY; Zhang XD Autophagy; 2015; 11(7):975-94. PubMed ID: 26018731 [TBL] [Abstract][Full Text] [Related]
3. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. Croft A; Tay KH; Boyd SC; Guo ST; Jiang CC; Lai F; Tseng HY; Jin L; Rizos H; Hersey P; Zhang XD J Invest Dermatol; 2014 Feb; 134(2):488-497. PubMed ID: 23921951 [TBL] [Abstract][Full Text] [Related]
4. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666 [No Abstract] [Full Text] [Related]
5. BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib. Nagasawa I; Kunimasa K; Tsukahara S; Tomida A Biochem Biophys Res Commun; 2017 Jan; 482(4):1491-1497. PubMed ID: 27965097 [TBL] [Abstract][Full Text] [Related]
6. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374 [TBL] [Abstract][Full Text] [Related]
7. ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. Peng U; Wang Z; Pei S; Ou Y; Hu P; Liu W; Song J Oncol Rep; 2017 Feb; 37(2):1270-1276. PubMed ID: 28035401 [TBL] [Abstract][Full Text] [Related]
8. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
9. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459 [TBL] [Abstract][Full Text] [Related]
10. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib. Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299 [TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. Søndergaard JN; Nazarian R; Wang Q; Guo D; Hsueh T; Mok S; Sazegar H; MacConaill LE; Barretina JG; Kehoe SM; Attar N; von Euw E; Zuckerman JE; Chmielowski B; Comin-Anduix B; Koya RC; Mischel PS; Lo RS; Ribas A J Transl Med; 2010 Apr; 8():39. PubMed ID: 20406486 [TBL] [Abstract][Full Text] [Related]
12. Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. Shenolikar S J Clin Invest; 2014 Mar; 124(3):973-6. PubMed ID: 24569370 [TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686 [TBL] [Abstract][Full Text] [Related]
14. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329 [TBL] [Abstract][Full Text] [Related]
15. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Wagenaar TR; Ma L; Roscoe B; Park SM; Bolon DN; Green MR Pigment Cell Melanoma Res; 2014 Jan; 27(1):124-33. PubMed ID: 24112705 [TBL] [Abstract][Full Text] [Related]
16. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas. Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867 [TBL] [Abstract][Full Text] [Related]
17. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Shi H; Kong X; Ribas A; Lo RS Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746 [TBL] [Abstract][Full Text] [Related]
18. The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib. Mondru AK; Wilkinson B; Aljasir MA; Alrumayh A; Greaves G; Emmett M; Albohairi S; Pritchard-Jones R; Cross MJ FEBS Lett; 2024 Aug; 598(16):2011-2027. PubMed ID: 38977937 [TBL] [Abstract][Full Text] [Related]
19. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
20. Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor. Corazao-Rozas P; Guerreschi P; Jendoubi M; André F; Jonneaux A; Scalbert C; Garçon G; Malet-Martino M; Balayssac S; Rocchi S; Savina A; Formstecher P; Mortier L; Kluza J; Marchetti P Oncotarget; 2013 Nov; 4(11):1986-98. PubMed ID: 24161908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]